Trethera

Coming – September 15

From Scientific Breakthrough to Breakthrough Medicine

Date and Time

September 15

–

4:00 PM ET / 1:00 PM PT

Details will be shared with confirmed attendees

About this Event

Developing a breakthrough medicine requires far more than a promising scientific discovery. It takes a deep understanding of disease biology, the ability to identify the right therapeutic target, sophisticated chemistry to turn that insight into a viable drug, and a clinical strategy capable of proving that it can meaningfully improve patients’ lives.

Join our all-star panel discussion for a fascinating conversation about how great science becomes great medicine, why so many promising ideas fail along the way, and what leading scientists look for when determining whether a discovery has the potential to become an important new therapy.
  • Larry Steinman, MD | Trethera Scientific Advisor, Neuroimmunology & Multiple Sclerosis
    Stanford Professor and member of the National Academies of Sciences and Medicine whose landmark research into brain inflammation helped lead to Tysabri, now used by more than 200,000 MS patients. A leading authority on neuroimmunology and autoimmune disease, Steinman has co-founded multiple life sciences companies, including Neurocrine Biosciences.
  • Michael E. Jung, PhD | Trethera Co-Founder, Medicinal Chemistry & Drug Discovery
    Distinguished Professor of Chemistry at UCLA and internationally recognized medicinal chemist whose laboratory produced two FDA-approved prostate cancer drugs, Xtandi and Erleada. Jung holds more than 25 patents and has published more than 250 articles. He brings decades of proven drug-discovery expertise to Trethera and the development of TRE-515.
  • Kenneth A. Schultz, MD | Trethera CEO & Chairman
    Physician and biotech executive leading Trethera and the clinical development of TRE-515. Schultz previously held leadership roles at Halozyme Therapeutics, Medtronic Diabetes and McKinsey & Company. He also serves as principal investigator on federally funded research advancing TRE-515 across cancer and autoimmune diseases.

Most biotechnology companies are built around a single disease. Trethera is built around an untapped biological pathway that offers multiple shots on goal.

Trethera’s drug, TRE-515, is a first-in-class oral therapy targets dCK, an enzyme in the DNA salvage pathway that is highly active across many solid tumors, autoimmune diseases, and inflammatory disorders.

TRE-515 completed Phase 1 dose escalation in over 30 patients with advanced solid tumors and subsequently received FDA Fast Track designation for metastatic prostate cancer. Encouraging observations from an FDA-authorized Expanded Access patient supported initiation of an ALS trial (n=6) at Massachusetts General Hospital. TRE-515 has also received an Orphan Drug designation for optic neuritis, inflammation of the optic nerve which typically causes vision loss and pain with eye movement.

Register today to reserve your space for this Fireside Chat with three legends of the biotech industry to learn more about this new pathway and the power the therapy that targets it has to treat a broad range of solid tumors, autoimmune diseases, and inflammatory disorders.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.